Ipamorelin vs. CJC-1295: Comparing GH Secretagogue Mechanisms

Ipamorelin (Aib-His-D-2-Nal-D-Phe-Lys-NH₂) is a pentapeptide GH secretagogue that acts as a selective agonist at the growth hormone secretagogue receptor 1a (GHS-R1a), also known as the ghrelin receptor. It was developed by Novo Nordisk and characterized in the late 1990s as a highly selective GHS with minimal off-target effects on cortisol, prolactin, or ACTH — a key differentiator from earlier GHS compounds like GHRP-6.

Bowers et al. demonstrated that ipamorelin produces dose-dependent GH release in rats with a short half-life of approximately 2 hours, consistent with a pulsatile GH secretion pattern. Its selectivity for GHS-R1a over other GPCR targets makes it a valuable tool compound for studying the ghrelin axis in isolation.

CJC-1295 is a synthetic analog of growth hormone-releasing hormone (GHRH 1-29) modified with a drug affinity complex (DAC) — a lysine residue conjugated to a maleimidoproprionic acid linker that enables covalent binding to serum albumin. This modification dramatically extends the half-life from the ~7 minutes of native GHRH to approximately 6–8 days in humans.

Teichman et al. (2006) published the first clinical pharmacokinetic data for CJC-1295, demonstrating sustained GH and IGF-1 elevation for up to 14 days following a single subcutaneous injection in healthy adults. This long-acting profile makes CJC-1295 useful for studying chronic GH axis stimulation in preclinical models.

Ipamorelin (GHS-R1a agonist) and CJC-1295 (GHRH receptor agonist) act through distinct but synergistic pathways. GHRH receptor activation increases cAMP and promotes GH synthesis, while GHS-R1a activation amplifies GH pulse amplitude through a separate Gq/phospholipase C pathway. Co-administration in rodent models produces supra-additive GH release compared to either compound alone.

This synergy has made the ipamorelin/CJC-1295 combination a standard protocol in preclinical GH axis research, allowing investigators to study the downstream effects of sustained IGF-1 elevation on body composition, bone density, and metabolic parameters.

Both compounds elevate circulating IGF-1 through hepatic GH receptor signaling. In rodent studies, chronic administration of CJC-1295 increased IGF-1 by 2–3 fold over baseline, with corresponding increases in lean body mass and reductions in adipose tissue. Ipamorelin alone produces more modest IGF-1 elevation consistent with its shorter duration of action.

Researchers should note that IGF-1 elevation is a downstream marker, not a direct effect of these peptides. The GH pulse pattern (pulsatile vs. continuous) influences the anabolic vs. metabolic partitioning of GH effects, a distinction that is important when designing preclinical protocols.